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SUMMARY 
Out of 108 patients on the rolls in the Lithium clinic, Madurai Medical College and Govt. Rajaji 
Hospital, Madurai, India, 47 patients suffering from affective disorders receiving lithium continuously for more 
than three years were analysed with a view to study the recurrences. Thirteen suffered no relapses while on 
lithium while nineteen experienced them while on lithium. Four were free from recurrences after lithium 
was withdrawn- Seven defaulted but suffered recurrences while in four the drug was withdrawn and in both 
the groups remission was achieved with readministration of lithium. The study reveals that lithium besides 
averting the recurrences can reduce the frequency, number, duration, intensity of episodes and improve the 
amenability to drugs. Among the symptoms, suicidal ideas and behaviour and insight were found to be in-
fluenced favourably by lithium. Among the factors that help favourable response to lithium were a positive 
family history of affective disorder, in the first degree relatives and lesser frequency and number of episodes 
in the pre-lithium period. A reappraisal of the natural history of the illness is called for in the light of lithium 
prophylaxis of manic depressive psychosis. 
In his now historic paper, 'Lithium 
salts in the treatment of psychotic excitement' 
Cade (1949) first observed the anti-manic 
properties of Lithium. It was however 
Schou's (1954) effor;s that led to an ex-
tensive clinical application and intensive 
investigation of the drug. In 1970, the 
Food and Drug Administration, United 
States approved Lithium for treating manic 
illness and for its prophylaxis. 
In view of the availability of lithium 
for prophylaxis of manic depressive psy-
chosis a clearer view of the course of the 
illness is called for. There have been 
conflicting reports on this. For example, 
according to Pollock et al. (1939) in the 
pre-lithium era, 58.1% of patients had 
only one attack, 26.1% two attacks, 9.3% 
three attacks and 6.5% more than thte: 
attacks. On the other hand, Rennie (1942) 
found that 70% of all patients had a second 
attack, 63.5% third attack and 45% fourth 
attack. This was especially so in those over 
forty years. Similarly, Angst et al. (1969) 
after examining the course of endogenous 
affective psychosis in 979 cases covering 
2260 disease cycles concluded that the 
course of recurrent mood disorders gets 
progressively more severe. In an earlier 
work from the first author's unit, 28% 
of 122 cases had only one attack while 
recurrence occurred in 63 cases. Chronicity 
was noticed in 11 patients (Venkoba Rao 
and Nammalvar, 1977). Surveying 6 major 
publications on the subject Zis and Goodwin 
(1979) concluded, that "the vast majority 
of patients with primary affective disorders 
experience several episodes during their 
life time." In this context of severe re-
curring nature of the disease, the use of 
lithium becomes relevant. Kraepelinean 
notion of manic depressive psychosis as a 
1 Professor and Head, Institute of Psychiatry, Madurai Medical College and Govt. Rajyi Hospital, Madurai-
625020, India. 
* Assistant Professor, Institute of Physiology. Madurai Medical College. Madurai-f>2."> 020, India. 
* Director aid Professor, Institute of Physiology, Madurai Medical College, Madurai-625 020. India. 
* Tutor in Psychiatry, Institute of Psychiatry, Madurai Medical College and Govt. Rajaji Hospital, Madurai-
625 020, India. LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDER  23 
benign disorder has lost much of its force 
(Kraepelin, 1921). 
Hartigan (1963) first reported on the 
prophylactic use of lithium for manic as well 
as depressive episodes. These beneficial 
results of lithium were later confirmed both 
by longitudinal trials that compared fre-
quency of attacks before and after adminis-
tration of lithium (Baastrup et al., 1970; 
Goppen et al., 1971 ; Hullin et al., 1972 
and Prien et al., 1973a) and also by match-
ing it against placebo and imipramine 
(Fieve et al., 1968 ; Fieve & Mendelewicz, 
1972 ; Prien et al., 1973b ; Stallone et al., 
1973). It is not clear whether lithium 
prevents the attacks by normalizing the 
mood by its normothymotic action as pro-
posed by Schou or it exercises a suppressive 
action by raising the patient's threshold to 
stressful life situations (Prien, 1979). 
Lithium Clinic : 
This communication is from the Lithium 
clinic functioning from 1975 in the Institute 
of Psychiatry, Madurai Medical College 
and Govt. Rajaji Hospital, Madurai, India. 
The clinic is held once a week. The earlier 
important publications from this clinic in-
clude clinical response to lithium (Venkoba 
Rao and Hariharasubramanian, 1978a and 
1978b) ; lithium induced E.C.G. changes 
(Venkoba Rao and Hariharasubramanian, 
1980) ; renal function studies (Venkoba 
Rao et al., 1979) ; renal biopsy studies 
(Venkoba Rao et al., 1981); memory impair-
ment (Sugumar et al., 1980) and the effects 
of lithium on the adrenal cortex and pineal 
gland (Parvathi Devi et al., 1973, 1976, 
1978 and 1980 ; Hariharasubramanian et 
al., 1976). It is felt appropriate at this 
point to make a critical assessment of the 
prophylactic benefits to the manic depres-
sive psychosis patients. 
Presently, there are 108 patients (M : 
70 ; F ; 38) on the rolls of the clinic. Serum 
lithium was estimated by Amdisen's flame 
photometric method. The serum levels 
were maintained between 0.6 and 1.2 m. 
mols/lit. Hullin (1979) suggest that the 
levels from 0.4 to 0.8 m. mols/lit would 
suffice for prophylaxis though recognising 
the need for higher levels of 0.6 to 1.2 
m. mols/lit for controlling acute manic 
episodes. 
AIMS 
The principal aims of the study are— 
(a) to compare the pre and post lithium 
pattern of recurrences in bipolar 
affective disorder ; 
(b) to ascertain whether lithium affects 
the features of the recurrences like 
their frequency, the duration, the 
number and intensity ; 
(c) to study how the factors like family 
history of affective illness in the 
first degree relatives, pre-lithium re-
currence pattern, clinical diagnosis, 
duration of the illness, age and 
sex of the patient, age at onset of 
illness and polarity of first and 
index episodes affect the response to 
lithium ; and 
(d) to observe the effect of lithium on 
suicide ideation and suicide be-
haviour and insight. 
MATERIAL AND METHOD 
Forty seven (M : 28 ; F : 19) among 
108 lithium clinic patients, lent themselves 
for study on the basis of the criterion of 
having been on lithium therapy for a minimum 
period of three years. The duration of 
therapy varied from three to six years. The 
age of the patients ranged from 21 to 63 
years (mean 39.5). The diagnoses were : 
Bipolar depression (MDP) (ICD 296.1) 
(N-40) ; Recurrent Mania (ICD 296.2 ; 
N-3) ; Unipolar depression (ICD 296.3 ; 
N—4). The duration of illness varied 
from two to fifteen years preceding lithium 
administration. The material (N —47) was 
divisible into five groups, based on the 
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Group I (N —13) : Total remission without 
recurrences ; continuously on lithium 
(Total duration pf treatment 3—5.5 
years) ; 
Group II (N—4) : Remission for 2 years 
while on lithium. Drug withdrawn ; 
No recurrences for 2 years following 
cessation of lithium. 
Group III (N —4) : Remission without 
recurrences for 2.5 years while on lithium; 
lithium was then withdrawn. Recurrences 
within a mean period of 8 months. 
Lithium restarted and maintained with 
remission and no further recurrence for 
1.5 years. 
Group IV (N —7) : Recurrences alter de-
faulting. Remitted after resuming 
lithium. No recurrences while on lithium 
for 3 years. 
Group V (N —19) : Recurrences occurred 
while on continuous lithium therapy. 
(Duration of treatment 3-6 years). 
Tables I and II offer data on the patients 
in all the groups. 
This is an open and single blind study 
without involving control or a comparison 
with other drugs or placebo. Each patient 
served as his own control and the compari-
son has been between pre- and post-lithium 
characteristics of recurrences. Such open 
and single blind studies have been reported 
(Schou, 1959 ; Wharton & Fieve, 1966 ; 
Blinder, 1968 ; and Vander Velde, 1970) 
and found to be quite valid on reappraisal 
TABLE I—Details of episodes (Pre-ilthium period) 
Factors 
Total No. of episodes ..—Manic 
—Depressive .. 
No. of episode per patient —Manic 
—-Depressive .. 
Frequency/year 
Duration of each episode 
Intensity of each episode 
Interval of remission 
between episode. 
TABLE 
Duration in years 
GI 
30 
32 
2.3 
2.5 
0.8 
3 
months 
Moderate/ 
severe 
10 
months. 
Gil 
3 
4 
0.75 
1.00 
0.5 
2.5 
months 
Mild/ 
Moderate 
1 
year. 
GIII 
3 
3 
0.75 
0.75 
0.5 
2.5 
months 
Moderate 
3 
years 
II—Duration of follow-up 
GI  G2  G3 
GIV 
18 
8 
2.6 
1.1 
0.8 
3 
months 
Severe 
1.4 
years. 
G4 
GV 
48 
45 
2.55 
2.35 
1.7 
3 
months 
Moderate 
severe 
8 
months. 
G5 
Duration of continous therapy —Mean 3.4 
—Range 3—5.5 
Duration of drug-free period 
Duration of therapy after restart-
ing 
Total duration of follow-up .. .. 3.4 
3 
3 
0.6 
1.5 
5.3 
3.2 4.4 
3_3.5 3—6 
1.5 
3 
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following the controlled studies referred to 
earlier. 
The criteria for recurrences were the 
persistence of disturbed mood and biological 
symptoms like insomnia, anorexia and alter-
ation of psychomotor activity for more than 
72 hours. 
OBSERVATIONS 
(a) Recurrences : The recurrences occur-
ring in Group V (supra) notwithstanding 
the continuous administration of lithium 
revealed the following features. The fre-
quency and the number of recurrences ,the 
duration and intensity of each of them 
were all significantly less when compared 
with the pre-lithium period. While there 
were 48 pre-lithium manic episodes, they 
fell to 27 in the post-lithium period. For 
the depressive episodes, the corresponding 
pre-lithium and post-lithium figures were 
45 and 28. The average number of episodes 
in the pre-lithium period was 4.9 per patient 
but it was 2.9 in the post-lithium stage. 
The frequency of episodes per year came 
down from 1.73 in the pre-lithium to 1.01 
in the post-lithium period. The mean 
duration of each episode which was 12 weeks 
prior to lithium fell to 3.8 weeks. While 
the intensity of the pre-lithium episodes was 
rated as moderate to severe, in the post-
lithium it was mild to moderate. The inter 
TABLE 
Factors 
No. of episodes .. .. .. —Manic 
Depress 
Average number per patient 
Frequency per year 
Mean duration of episode (in weeks) 
Intensity of episodes 
Mean interval of remission (in months) 
episodal period of 8 months during pre-
lithium period lengthened to 11.5 months 
during lithium administration (Table III). 
The data showed a lack of any pre-
ferential prophylactic property of lithium 
either for manic or depressive episodes in 
the bipolar patients. Both responded iden-
tically. In respect of the unipolar depression 
it is difficult to draw any conclusion since 
there were only four such patients in the 
series though three responded with no 
recurrences (Two each in Group I and II). 
Thus pre and post-lithium recurrences 
reveal the mitigating effects of lithium al-
though recurrences could not be totally 
averted in this group. Additionally the 
relapses were easily controlled by increasing 
the dose of lithium or by combining it with 
phenothiazines or anti-depressants depend-
ing upon the episode. None of the patients 
required hospitalisation. On the other 
hand, before the institution of lithium the 
relapses were treated by ECT and hospital-
ization in addition to anti-depressants and 
phenothiazines. There were six instances of 
recurrence in the post-lithium phase where 
they were preceded by stressful life events. 
It is likely that contrary to the claim, 
lithium did not lessen the vulnerability of 
the patients to life's stresses. 
(b) Clinical features of the recurrences : 
Clinical features were studied with special 
III 
Pre-lithium Post-lithium % Change 
48 
45 
4.9 
1.73 
12 
27 
28 
2.9 
1.01 
3.8 
56.25 
62.2 
59.2 
38.4 
63.2 
.. Moderate/ Mild/ 
severe moderate 
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reference to the occurrence of suicidal tration on their own. The time taken in 
thoughts and attempts and preservation of all the groups for induction of remission is 
insight, both before and in post-lithium indicated in Table IV. 
stages. Though eight patients had suicidal 
ideas and two attempted suicide in the series 
during pre-lithium period, none experienced 
them nor made attempt during lithium 
treatment. The receding of suicidal ideas 
Factors affecting the responses : 
Age, and sex of the patients, the age 
at the onset of illness, the duration of the 
illness and the polarity of the first or index 
and absence of suicidal attempts while under episodes did not influence the successful 
lithium even during recurrences adds a 
new dimension in suicide prevention pro-
gramme. This also brings a fresh look at 
the course and natural history of the illness. 
In an earlier study on the course and out-
come of depression from the department 
45% experienced suicidal ideas, 25% at-
tempted suicide with one ending in suicide 
(Venkoba Rao and Nammalvar, 1977). 
There have been no suicidal death or at-
tempt among the patients in all the five 
groups in the post lithium period. 
It is interesting to note that several 
patients who reported to the clinic during 
the recurrences were aware of a change in 
their mental and physical well being. While 
before the starting of lithium therapy, the 
insight was poor, but when under lithium 
the patients were able to sense the oncoming 
recurrence and seek relief in the clinic. This 
adds considerably to the early management 
of relapses and may explain the shorter 
duration of episodes under lithiuni. This 
was not so in those with non-drug com-
pliance (Group IV). 
Time taken for remission : 
The period required for remission after 
restarting lithium was highest (6 weeks) 
in Group IV (defaulters) indicating the 
unfavourable eftects of irregular adminis-
lithium prophylaxis either in Group I or 
the not so successful response in other groups 
(Table V). On the other hand, the occur-
rence of affective illness in the first degree 
relatives was more frequent in Group I 
than in the other groups. It was nearly 
five times more frequent than in the Group 
V patients. Affective illness in the second 
degree relatives did not bear such relation 
(Table VI). Attention was drawn to this 
by Fieve (1976) while summarising the 
available literature. 
DISCUSSION 
Our data offer strong support for the 
lithium prophylaxis in Bipolar affective 
disorder. Out of 47 probands receiving 
lithium for more than three years, 28 patients 
responded to lithium either with no recur-
rences at all while on drug (N —13) ; or 
after its withdrawal (N—4) or after re-
administration following voluntary with-
drawal (N—4) and defaulting (N—7). 
Nineteen patients experienced recurrences 
while on continuous treatment but they 
were marked by lessened frcquency,number, 
intensity and duration and a higher suscept-
ibility to drug treatment without hospitalis-
ation or EGT. Such observations have 
been refeired to by Fieve (1976). There 
have been numerous favourable reports on 
TABLE IV—Time taken for remission after starling lithium therapy 
Duration in weeks  Gl  G2  G3  G4  G5 
Period for remission 
Period for second remission 
2.5  3.5  3.5  3.8 
The earlier onset of remission in Gl, G2, and G3 patients was statistically significant. LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDER 
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27 
Factors  Gl  G2  G3  G4  G5 
Age 
Sex : 
Total duration of illness (years) 
Age at onset of illness (years) 
Polarity of first episode 
Polarity of index episode 
Range 
Mean 
Male 
Female 
-Range 
Mean 
-Manic 
-Depression 
-Manic 
-Depressive 
(N* 
. 30 
. 22-
•• 
= 13) 
—63 
45.5 
9 
4 
7.5 
—50 
38.5 
9 
4 
10 
3 
(N= 
22 
20 
=4) 
—55 
38.8 
4 
•• 
2 
-45 
32.5 
1 
3 
1 
3 
(N 
45-
35-
=4) 
—50 
46.2 
2 
2 
5.1 
-40 
37.5 
1 
3 
3 
1 
(N=7 
35—55 
42.5 
6 
1 
15 
25—35 
29.3 
3 
4 
6 
1 
(N = 19) 
25—60 
41.5 
10 
9 
5.3 
20—55 
32.5 
9 
10 
11 
8 
TABLE VI—Family History of Mental Illness 
Nature of 
illness 
Affective Illness 
Degree of Gl G2 G3 G4 G5 
relatives (N=13) (N=4) (N=4) (N = 7) (N=19) 
I Degree .. 3 1 1 .. 1 
relatives .. (23%) (25%) (25%) (5%) 
II Decree rela-
tives. 
1 
lithium prophylaxis in bipolar illness 
(Hartigan, 1963 ; Baastrup & Schou, 1967 ; 
Prien et al., 1979 ; and Narayanan et al., 
1979). The placebo control studies have 
revealed that about 30% of manic-depressives 
on lithium experienced a relapse during a 
two-year follow-up period (Baastrup et al., 
1970 ; Prien et al., 1973 ; Stallone et al., 
1973 ; Goppen et al., 1971). The relapse 
rate by contrast was 90% among those 
receiving placebo. 
The effectiveness of the prophylactic 
effect in unipolar depressives has been 
advanced by Schou (1979) and Prien (1979) 
amongst others. However, in our series 
the number of unipolar depiessives is too 
small to help draw any firm conclusion. 
It is intriguing that the Group I patients 
(N — 13) experienced no relapse while those 
Group V suffered relapses though miti-
gated although both groups were receiving 
lithium continuously. A higher incidence 
of affective disorder in the first degree re-
latives, lesser frequency of episodes, and 
lesser time required for inducing remission 
were associated with the absence of relapses 
in Groups I and II and their easy control 
in Group III. This state of affair did not 
prevail in Group V. Thus the type of 
response calls for further study over the 
possibility whether one is dealing with 
different types of affective disorders within 
the bipolar group in relation to lithium 
response. Spitzer et al. (1978) have stated 
that the illness lasting for over 2 years be-
comes treatment resistent. Rapid cyclers 
(four or more episodes per year) do not 
fare well with lithium as was pointed out 
by Dunner and Fieve (1974). 
With the advent of prophylaxis, a 28  A. VENKOBA RAO et al. 
critical reappraisal of the natural history of 
the disease and course becomes necessary. 
The episodes of either mania or depression 
get modified under the influence of con-
tinuous lithium therapy in regard to fre-
quency, number, duration as well as 
symptom content. From the present study 
two other important findings have emerged. 
One is the complete absence of suicidal 
ideation and suicidal attempt during re-
currences. One should not overlook those 
in Group I who enjoyed total absence of 
recurrences while assessing the risk of 
suicide. Barraclough (1972) has calculated 
that one-fifth of the suicides in MDP 
patients was prevcntible by lithium treat-
ment. Sainsbury (1980) by extrapolating 
this figure, claimed that in England the 
total suicides would have been less by 750 
per year. 
The other clinical feature, the retention 
of insight in a large majority of patients 
enabled them to sense that the recurrence 
was around the corner and report at the 
clinic earlier thereby facilitating early treat-
ment and a quicker control of symptoms. 
In years to come there is a likelihood of 
a change in the symptomatology of the 
manic-depressive episodes when it is claimed 
that litliium specifically alters the core 
symptoms viz. the affective and ideational 
features of the illness (Goodwin and Zis 
1979). One should therefore be prepared to 
recognize the "truncated" or "metamor-
phosed" episodes of effective illness in 
patients already on lithium. This situation 
is analogous to the treated long term illnesses 
like Tubercular disease. 
One other major index of prophylactic 
benefits from lithium apart from the lower-
ing the number of recurrences and suicide 
control is the reduction in cost involved in 
the management of the pat ient. None of the 
patients in the present series needed hospital-
ization for treatment of recurrences, nor 
were the ECTs resorted to avoiding thereby 
the fear that they generate. They were 
all effectively controlled with drugs. It has 
been estimated that around 4 billion dollars 
have been saved in the United States during 
the decade following the approval of lithium 
by FDA for use in mania and as prophy-
laxis for bipolar illness (Reifman and Wyatt, 
1980). This was arrived by assessing the 
economy in the psychiatric care and in-
creased production by MDP patients treated 
with lithium. 
It is not possible with the present 
data to state categorically as to when 
the lithium therapy should be stopped. 
For instance, in Group II, only four res-
ponded with a remission after a cessation 
of lithium for two years. The Group I 
patients (N —13) were enjoying remission 
but were on lithium. On the other hand, 
the Group V patients (N —19) suffered 
recurrences even while on lithium. How-
ever, it is clear that in a certain group of 
patients lithium could be withdrawn without 
the risk of recurrences. Further studies are 
awaited in this regard. 
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